<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01008774</url>
  </required_header>
  <id_info>
    <org_study_id>DOCET_L_04449</org_study_id>
    <nct_id>NCT01008774</nct_id>
  </id_info>
  <brief_title>START: Swiss Taxotere Alopecia Prevention Trial</brief_title>
  <official_title>A Comparison of Different Scalp Cooling Systems for the Prevention of Chemotherapy Induced Alopecia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objective:

        -  Rate of complete chemotherapy induced alopecia (WHO grade III or IV, physician grading)

      Secondary objective:

        -  Compliance to scalp cooling procedure

        -  Received number of cycles of chemotherapy in each subgroup

        -  Patient perception of scalp cooling procedure

        -  Side effects of scalp cooling systems
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Grade III or IV alopecia according to the WHO criteria</measure>
    <time_frame>D1 of each cycle and D+21 after last cycle of chemotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compliance to scalp cooling procedure</measure>
    <time_frame>D1 of each cycle and D+21 after last cycle of chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects of scalp cooling systems</measure>
    <time_frame>D1 of each cycle and D+21 after last cycle of chemotherapy</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">239</enrollment>
  <condition>Neoplasms</condition>
  <condition>Alopecia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paxman Cooling Machine</intervention_name>
    <description>Scalp cooling procedures</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cold Caps</intervention_name>
    <description>Scalp cooling procedures</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any solid tumor malignancy receiving docetaxel (TaxotereÂ®) 1st line chemotherapy
             treatment with the exception of regimen containing concomitant anthracycline
             treatment; sequential anthracycline/docetaxel treatment is permitted.

          -  Performance Status ECOG &lt;= 2

          -  Absence of alopecia at inclusion

        Exclusion Criteria:

          -  Chemotherapy regimen including concomitant anthracycline treatment

          -  Raynaud's disease or phenomenon

          -  Cold agglutinin disease

          -  Cryoglobulinemia

          -  Cryofibrinogenemia

          -  Scalp metastasis

          -  Pregnancy or Lactation

          -  Preexisting alopecia of any grade; notably androgenetic alopecia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2009</study_first_submitted>
  <study_first_submitted_qc>November 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2009</study_first_posted>
  <last_update_submitted>January 20, 2012</last_update_submitted>
  <last_update_submitted_qc>January 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

